LSV Asset Management Trims Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

LSV Asset Management lowered its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 1.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,343,227 shares of the specialty pharmaceutical company's stock after selling 28,950 shares during the quarter. LSV Asset Management owned about 3.72% of Jazz Pharmaceuticals worth $288,217,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Daiwa Securities Group Inc. increased its stake in shares of Jazz Pharmaceuticals by 2.5% in the third quarter. Daiwa Securities Group Inc. now owns 4,076 shares of the specialty pharmaceutical company's stock valued at $528,000 after buying an additional 100 shares during the period. Waterfront Wealth Inc. increased its position in Jazz Pharmaceuticals by 1.2% in the 4th quarter. Waterfront Wealth Inc. now owns 8,633 shares of the specialty pharmaceutical company's stock valued at $1,062,000 after acquiring an additional 103 shares during the period. Prime Capital Investment Advisors LLC raised its stake in shares of Jazz Pharmaceuticals by 4.3% during the fourth quarter. Prime Capital Investment Advisors LLC now owns 2,646 shares of the specialty pharmaceutical company's stock valued at $325,000 after acquiring an additional 108 shares during the last quarter. Johnson Investment Counsel Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 0.8% during the third quarter. Johnson Investment Counsel Inc. now owns 13,096 shares of the specialty pharmaceutical company's stock worth $1,695,000 after purchasing an additional 110 shares during the period. Finally, Fifth Third Bancorp grew its stake in shares of Jazz Pharmaceuticals by 2.2% in the third quarter. Fifth Third Bancorp now owns 5,339 shares of the specialty pharmaceutical company's stock worth $691,000 after purchasing an additional 114 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Activity

In other news, CFO Philip L. Johnson purchased 12,000 shares of the company's stock in a transaction that occurred on Friday, March 1st. The shares were bought at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now directly owns 27,932 shares of the company's stock, valued at $3,342,063.80. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson acquired 12,000 shares of the business's stock in a transaction on Friday, March 1st. The shares were acquired at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the transaction, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CAO Patricia Carr sold 1,936 shares of the firm's stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the sale, the chief accounting officer now directly owns 8,364 shares of the company's stock, valued at $1,000,668.96. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Stifel Nicolaus raised their price objective on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a "buy" rating in a research report on Friday, March 15th. Cantor Fitzgerald restated an "overweight" rating and issued a $180.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. UBS Group decreased their price objective on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a "neutral" rating for the company in a research report on Friday, March 1st. Piper Sandler lifted their price objective on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 20th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $195.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $192.75.

Jazz Pharmaceuticals Stock Up 0.7 %

Shares of JAZZ traded up $0.72 during trading hours on Friday, reaching $110.01. The stock had a trading volume of 693,769 shares, compared to its average volume of 597,957. Jazz Pharmaceuticals plc has a 12 month low of $103.01 and a 12 month high of $146.70. The company has a market capitalization of $6.94 billion, a price-to-earnings ratio of 22.68, a P/E/G ratio of 1.52 and a beta of 0.63. The firm has a 50-day simple moving average of $116.44 and a 200 day simple moving average of $120.94. The company has a current ratio of 2.27, a quick ratio of 1.85 and a debt-to-equity ratio of 1.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts' consensus estimates of $4.44 by ($0.04). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Equities research analysts predict that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.